Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 49
Filter
1.
Acta Psychiatr Scand ; 141(4): 362-373, 2020 04.
Article in English | MEDLINE | ID: mdl-31785112

ABSTRACT

OBJECTIVE: Omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acid (PUFA) alterations in patients with major depressive disorder (MDD) have been shown to persist after remission. Whether these alterations are risk factors for MDD recurrence remains unknown. Here, we examined whether fatty acids predict time until MDD recurrence in remitted MDD patients. METHODS: Data were used from remitted MDD patients of the Netherlands Study of Depression and Anxiety (n = 356) and the Depression Evaluation Longitudinal Therapy Assessment studies (n = 118). Associations of FAs with time until MDD recurrence up to 8-year follow-up were analyzed using Cox regression analyses. Study-specific estimates were pooled using mega- and meta-analysis techniques. RESULTS: 27.5% (NESDA) and 56.8% (DELTA) participants had an MDD recurrence. Pooled results showed that no FA was significantly associated with time until MDD recurrence (n-3 PUFAs: hazard ratio (HR) = 1.17, 95% confidence interval (CI) = 0.98-1.41, P = 0.082; n-6 PUFAs: HR = 1.08, 95% CI = 0.84-1.38, P = 0.55). CONCLUSION: In remitted MDD patients, circulating PUFAs were not associated with prospective risk of MDD recurrence. Consequently, circulating PUFAs are unlikely to reflect a vulnerability marker for recurrence, so correcting n-3 PUFA 'deficits' through supplementation does not seem a promising option to prevent MDD recurrence.


Subject(s)
Depressive Disorder, Major/metabolism , Fatty Acids/metabolism , Adolescent , Adult , Aged , Depressive Disorder, Major/blood , Fatty Acids/blood , Fatty Acids, Omega-3/blood , Fatty Acids, Omega-3/metabolism , Fatty Acids, Omega-6/blood , Fatty Acids, Omega-6/metabolism , Female , Humans , Male , Middle Aged , Netherlands , Prospective Studies , Recurrence , Regression Analysis , Young Adult
2.
Psychoneuroendocrinology ; 100: 203-212, 2019 02.
Article in English | MEDLINE | ID: mdl-30388594

ABSTRACT

BACKGROUND: Alterations in hypothalamic-pituitary-adrenal (HPA)-axis activity, fatty acid metabolism, and their relation have been associated with (recurrent) major depressive disorder (MDD), although conflicting findings exist. AIMS: To determine whether alterations in HPA-axis activity and fatty acids in recurrent MDD remain during remission (i.e. reflect a potential trait factor). Furthermore, to test the association between HPA-axis activity and fatty acids in patients versus controls. METHODS: We cross-sectionally compared 73 remitted unmedicated recurrent MDD patients with 46 matched never-depressed controls. Measurements included salivary cortisol and dehydroepiandrosterone sulfate (DHEAS) (awakening, evening, and after sad mood induction) and erythrocyte fatty acid parameters: (I) three main fatty acids [omega-3 docosahexaenoic acid (DHA), and the omega-3 eicosapentaenoic acid/omega-6 arachidonic acid (EPA/AA)-ratio], and (II) structural fatty acid indices [chain length, unsaturation and peroxidation]. RESULTS: Patients showed higher cortisol awakening responses (p = 0.006) and lower evening cortisol/DHEAS ratios (p = 0.044) compared to matched controls. Fatty acids did not differ between patients and controls, but HPA-axis indicators were significantly associated with fatty acid parameters in both groups (0.001 ≤ p ≤ 0.043). Patients and controls significantly differed in the relations between awakening DHEAS or cortisol/DHEAS ratios and fatty acid parameters, including unsaturation and peroxidation indices (0.001≤ p ≤ 0.034). Significance remained after correction for confounders. CONCLUSIONS: Our results further support alterations in HPA-axis activity, i.e. a lower baseline, but higher responsiveness of awakening cortisol, in remitted medication-free recurrent MDD patients. Furthermore, the relationship between HPA-axis and fatty acids showed significant differences in recurrent MDD patients versus controls. Prospective research is needed to determine the predictive value of this relationship for MDD recurrence.


Subject(s)
Dehydroepiandrosterone Sulfate/metabolism , Depression/metabolism , Fatty Acids/blood , Hydrocortisone/metabolism , Adult , Aged , Case-Control Studies , Cross-Sectional Studies , Dehydroepiandrosterone Sulfate/analysis , Depression/blood , Depression/epidemiology , Depression/pathology , Female , Humans , Hydrocortisone/analysis , Hypothalamo-Hypophyseal System/metabolism , Male , Middle Aged , Pituitary-Adrenal System/metabolism , Recurrence , Saliva/chemistry , Saliva/metabolism
3.
J Inherit Metab Dis ; 41(4): 597-611, 2018 07.
Article in English | MEDLINE | ID: mdl-29524021

ABSTRACT

Continuous research into the pathophysiology of psychiatric disorders, such as major depressive disorder (MDD), posttraumatic stress disorder (PTSD), and schizophrenia, suggests an important role for metabolism. This narrative review will provide an up-to-date summary of how metabolism is thought to be involved in the pathophysiology of these psychiatric disorders. We will focus on (I) the important role of fatty acids in these metabolic alterations, (II) whether fatty acid alterations represent epiphenomena or risk factors, and (III) similarities and dissociations in fatty acid alterations between different psychiatric disorders. (Historical) epidemiological evidence links fatty acid intake to psychiatric disorder prevalence, corroborated by altered fatty acid concentrations measured in psychiatric patients. These fatty acid alterations are connected with other concomitant pathophysiological mechanisms, including biological stress (hypothalamic-pituitary-adrenal (HPA)-axis and oxidative stress), inflammation, and brain network structure and function. Metabolomics and lipidomics studies are underway to more deeply investigate this complex network of associated neurometabolic alterations. Supplementation of fatty acids as disease-modifying nutraceuticals has clinical potential, particularly add-on eicosapentaenoic acid (EPA) in depressed patients with markers of increased inflammation. However, by interpreting the observed fatty acid alterations as partly (mal)adaptive phenomena, we attempt to nuance translational expectations and provide new clinical applications for these novel neurometabolic insights, e.g., to predict treatment response or depression recurrence. In conclusion, placing fatty acids in context can contribute to further understanding and optimized treatment of psychiatric disorders, in order to diminish their overwhelming burden of disease.


Subject(s)
Fatty Acids/metabolism , Hypothalamo-Hypophyseal System/metabolism , Mental Disorders/metabolism , Pituitary-Adrenal System/metabolism , Eicosapentaenoic Acid/analogs & derivatives , Humans , Inflammation/metabolism , Mental Disorders/physiopathology , Metabolism, Inborn Errors/metabolism , Oxidative Stress
4.
Psychoneuroendocrinology ; 79: 84-92, 2017 05.
Article in English | MEDLINE | ID: mdl-28262603

ABSTRACT

BACKGROUND: A better understanding of factors underlying antidepressant non-response may improve the prediction of which patients will respond to what treatment. Major depressive disorder (MDD) is associated with alterations in fatty acid metabolism, (neuro)inflammation and amygdala-reactivity. However, their mutual relations, and the extent to which they are associated with prospective antidepressant-response, remain unknown. PURPOSE: To test (I) alterations in (neuro)inflammation and its associations with fatty acid metabolism and amygdala-reactivity in MDD-patients compared to controls, and (II) whether these alterations are associated with prospective paroxetine response. METHODS: We compared 70 unmedicated MDD-patients with 51 matched healthy controls at baseline, regarding erythrocyte membrane omega-6 arachidonic acid (AA), inflammation [serum (high-sensitivity) C-reactive protein (CRP)], and in a subgroup amygdala-reactivity to emotional faces using functional magnetic resonance imaging (fMRI) (N=42). Subsequently, we treated patients with 12 weeks paroxetine, and repeated baseline measures after 6 and 12 weeks to compare non-responders, early-responders (response at 6 weeks), and late-responders (response at 12 weeks). RESULTS: Compared to controls, MDD-patients showed higher CRP (p=0.016) and AA (p=0.019) after adjustment for confounders at baseline. AA and CRP were mutually correlated (p=0.043). In addition, patients showed a more negative relation between AA and left amygdala-reactivity (p=0.014). Moreover, AA and CRP were associated with antidepressant-response: early responders showed lower AA (p=0.018) and higher CRP-concentrations (p=0.008) than non-responders throughout the study. CONCLUSION: Higher observed CRP and AA, their mutual association, and relation with amygdala-reactivity, are corroborative with a role for (neuro)inflammation in MDD. In addition, observed associations of these factors with prospective antidepressant-response suggest a potential role as biomarkers. Future studies in independent samples are needed to replicate and test the clinical applicability of these biological predictors for treatment response to result in a precision/personalized medicine approach for treatment.


Subject(s)
Amygdala/drug effects , Antidepressive Agents/therapeutic use , Depressive Disorder, Major/drug therapy , Fatty Acids/metabolism , Paroxetine/therapeutic use , Adult , Amygdala/diagnostic imaging , Antidepressive Agents/pharmacology , C-Reactive Protein/metabolism , Depressive Disorder, Major/diagnostic imaging , Depressive Disorder, Major/metabolism , Female , Humans , Inflammation/metabolism , Lipid Metabolism/drug effects , Magnetic Resonance Imaging , Male , Middle Aged , Paroxetine/pharmacology , Prospective Studies
5.
Transl Psychiatry ; 6: e756, 2016 Mar 15.
Article in English | MEDLINE | ID: mdl-26978738

ABSTRACT

Omega-3 polyunsaturated fatty acid (PUFA) supplementation has been proposed as (adjuvant) treatment for major depressive disorder (MDD). In the present meta-analysis, we pooled randomized placebo-controlled trials assessing the effects of omega-3 PUFA supplementation on depressive symptoms in MDD. Moreover, we performed meta-regression to test whether supplementation effects depended on eicosapentaenoic acid (EPA) or docosahexaenoic acid dose, their ratio, study duration, participants' age, percentage antidepressant users, baseline MDD symptom severity, publication year and study quality. To limit heterogeneity, we only included studies in adult patients with MDD assessed using standardized clinical interviews, and excluded studies that specifically studied perinatal/perimenopausal or comorbid MDD. Our PubMED/EMBASE search resulted in 1955 articles, from which we included 13 studies providing 1233 participants. After taking potential publication bias into account, meta-analysis showed an overall beneficial effect of omega-3 PUFAs on depressive symptoms in MDD (standardized mean difference=0.398 (0.114-0.682), P=0.006, random-effects model). As an explanation for significant heterogeneity (I(2)=73.36, P<0.001), meta-regression showed that higher EPA dose (ß=0.00037 (0.00009-0.00065), P=0.009), higher percentage antidepressant users (ß=0.0058 (0.00017-0.01144), P=0.044) and earlier publication year (ß=-0.0735 (-0.143 to 0.004), P=0.04) were significantly associated with better outcome for PUFA supplementation. Additional sensitivity analyses were performed. In conclusion, present meta-analysis suggested a beneficial overall effect of omega-3 PUFA supplementation in MDD patients, especially for higher doses of EPA and in participants taking antidepressants. Future precision medicine trials should establish whether possible interactions between EPA and antidepressants could provide targets to improve antidepressant response and its prediction. Furthermore, potential long-term biochemical side effects of high-dosed add-on EPA supplementation should be carefully monitored.


Subject(s)
Antidepressive Agents/therapeutic use , Depression/drug therapy , Depressive Disorder, Major/drug therapy , Dietary Supplements , Docosahexaenoic Acids/therapeutic use , Eicosapentaenoic Acid/therapeutic use , Fatty Acids, Omega-3/therapeutic use , Humans , Randomized Controlled Trials as Topic , Regression Analysis
6.
Psychoneuroendocrinology ; 59: 91-101, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26036454

ABSTRACT

BACKGROUND: Major depressive disorder (MDD) has been associated with low dehydroepiandrosterone-sulphate (DHEAS), - particularly relative to high cortisol - although conflicting findings exist. Moreover, it is unclear whether low DHEAS is only present during the depressive state, or manifests as a trait that may reflect vulnerability for recurrence. Therefore, we longitudinally tested whether low DHEAS and high cortisol/DHEAS-ratio in recurrent MDD (I) reflects a trait, and/or (II) varies with depressive state. In addition, we tested associations with (III) previous MDD-episodes, (IV) prospective recurrence, and (V) effects of cognitive therapy. METHODS: At study-entry, we cross-sectionally compared morning and evening salivary DHEAS and molar cortisol/DHEAS-ratio of 187 remitted recurrent MDD-patients with 72 matched controls. Subsequently, patients participated in an 8-week randomized controlled cognitive therapy trial. We repeated salivary measures after 3 months and 2 years. We measured clinical symptoms during a 10-year follow-up. RESULTS: Remitted patients showed steeper diurnal DHEAS-decline (p<.005) and a flatter diurnal profile of cortisol/DHEAS-ratio (p<.001) than controls. We found no state-effect in DHEAS or cortisol/DHEAS-ratio throughout follow-up and no association with number of previous episodes. Higher morning cortisol/DHEAS-ratio predicted shorter time till recurrence over the 10-year follow-up in interaction with the effects of cognitive therapy (p<.05). Finally, cognitive therapy did not influence DHEAS or cortisol/DHEAS-ratio. CONCLUSIONS: Diurnal profiles of DHEAS and cortisol/DHEAS-ratio remain equally altered in between depressive episodes, and may predict future recurrence. This suggests they represent an endophenotypic vulnerability trait rather than a state-effect, which provides a new road to understand recurrent depression and its prevention. TRIAL REGISTRATION: www.isrctn.com/ISRCTN68246470.


Subject(s)
Dehydroepiandrosterone Sulfate/metabolism , Depressive Disorder, Major/metabolism , Hydrocortisone/metabolism , Adult , Case-Control Studies , Cognitive Behavioral Therapy , Cross-Sectional Studies , Depressive Disorder, Major/therapy , Female , Humans , Hypothalamo-Hypophyseal System/metabolism , Longitudinal Studies , Male , Middle Aged , Pituitary-Adrenal System/metabolism , Predictive Value of Tests , Recurrence , Saliva/metabolism , Treatment Outcome
7.
J Affect Disord ; 166: 115-23, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25012419

ABSTRACT

BACKGROUND: An important biological factor suggested in the pathophysiology of (recurrent) Major Depressive Disorder (MDD) concerns a polymorphism in a gene encoding for the MTHFR-enzyme of the one-carbon (1-C)-metabolism. Integratively investigating key 1-C-components (folate, homocysteine, vitamin B6 and B12), including the possible effects of antidepressant medication and depressive state, could provide more insight in the possible association between the MTHFR-polymorphism and recurrent MDD. METHODS: We compared the MTHFR C677T-polymorphism together with the key 1-C-components in clinically ascertained patients with recurrent MDD (n=137) to age- and gender-matched healthy controls (n=73). RESULTS: First, patients had lower folate (t=2.25; p=.025) as compared to controls; a difference that resolved after correction for demographics (t=1.22; p=.223). Second, patients that were depressed during sampling had lower vitamin B6 (t=-2.070; p=.038) and higher homocysteine (t=2.404; p=.016) compared to those in remission. Finally, current use of antidepressants had no influence on the 1-C-components. CONCLUSIONS: Despite investigation of a specific recurrently depressed patient population, we found no clear associations with the 1-C-cycle, except for higher homocysteine and lower vitamin B6 during the depressed state. This suggests that 1-C-cycle alterations in MDD are state-associated, possibly resulting from high levels of acute (psychological) stress, and may provide a treatment target to reduce cardiovascular risk in this population.


Subject(s)
Antidepressive Agents/therapeutic use , Carbon/metabolism , Depressive Disorder, Major/drug therapy , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Polymorphism, Genetic , Adult , Case-Control Studies , Depressive Disorder, Major/genetics , Female , Folic Acid/blood , Homocysteine/blood , Humans , Male , Middle Aged , Recurrence , Vitamin B 12/blood , Vitamin B 6/blood
8.
Acta Psychiatr Scand ; 130(3): 163-80, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24649967

ABSTRACT

OBJECTIVE: Cardiovascular disease (CVD) is the leading cause of death in severe psychiatric disorders (depression, schizophrenia). Here, we provide evidence of how the effects of oxidative stress on fatty acid (FA) and one-carbon (1-C) cycle metabolism, which may initially represent adaptive responses, might underlie comorbidity between CVD and psychiatric disorders. METHOD: We conducted a literature search and integrated data in a narrative review. RESULTS: Oxidative stress, mainly generated in mitochondria, is implicated in both psychiatric and cardiovascular pathophysiology. Oxidative stress affects the intrinsically linked FA and 1-C cycle metabolism: FAs decrease in chain length and unsaturation (particularly omega-3 polyunsaturated FAs), and lipid peroxidation products increase; the 1-C cycle shifts from the methylation to transsulfuration pathway (lower folate and higher homocysteine and antioxidant glutathione). Interestingly, corresponding alterations were reported in psychiatric disorders and CVD. Potential mechanisms through which FA and 1-C cycle metabolism may be involved in brain (neurocognition, mood regulation) and cardiovascular system functioning (inflammation, thrombosis) include membrane peroxidizability and fluidity, eicosanoid synthesis, neuroprotection and epigenetics. CONCLUSION: While oxidative-stress-induced alterations in FA and 1-C metabolism may initially enhance oxidative stress resistance, persisting chronically, they may cause damage possibly underlying (co-occurrence of) psychiatric disorders and CVD. This might have implications for research into diagnosis and (preventive) treatment of (CVD in) psychiatric patients.


Subject(s)
Cardiovascular Diseases/metabolism , Fatty Acids/metabolism , Homocysteine/metabolism , Mental Disorders/metabolism , Metabolic Networks and Pathways/physiology , Oxidative Stress/physiology , Humans
9.
Transl Psychiatry ; 3: e288, 2013 Jul 30.
Article in English | MEDLINE | ID: mdl-23900311

ABSTRACT

Childhood trauma is associated with the onset and recurrence of major depressive disorder (MDD). The thermolabile T variant of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism (rs1801133) is associated with a limited (oxidative) stress defense. Therefore, C677T MTHFR could be a potential predictor for depressive symptomatology and MDD recurrence in the context of traumatic stress during early life. We investigated the interaction between the C677T MTHFR variant and exposure to traumatic childhood events (TCEs) on MDD recurrence during a 5.5-year follow-up in a discovery sample of 124 patients with recurrent MDD and, in an independent replication sample, on depressive symptomatology in 665 healthy individuals from the general population. In the discovery sample, Cox regression analysis revealed a significant interaction between MTHFR genotype and TCEs on MDD recurrence (P=0.017). Over the 5.5-year follow-up period, median time to recurrence was 191 days for T-allele carrying patients who experienced TCEs (T+ and TCE+); 461 days for T- and TCE+ patients; 773 days for T+ and TCE- patients and 866 days for T- and TCE- patients. In the replication sample, a significant interaction was present between the MTHFR genotype and TCEs on depressive symptomatology (P=0.002). Our results show that the effects of TCEs on the prospectively assessed recurrence of MDD and self-reported depressive symptoms in the general population depend on the MTHFR genotype. In conclusion, T-allele carriers may be at an increased risk for depressive symptoms or MDD recurrence after exposure to childhood trauma.


Subject(s)
Depressive Disorder, Major/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Polymorphism, Single Nucleotide/genetics , Stress, Psychological/genetics , Adolescent , Adult , Alleles , Child , Depression/etiology , Depression/genetics , Depressive Disorder, Major/etiology , Female , Genetic Predisposition to Disease/genetics , Genotype , Humans , Male , Middle Aged , Proportional Hazards Models , Psychiatric Status Rating Scales , Recurrence , Risk Factors , Stress, Psychological/complications , Young Adult
11.
J Affect Disord ; 126(1-2): 282-6, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20466431

ABSTRACT

BACKGROUND: Depression is common in individuals with diabetes. The present study is the first randomized controlled trial to test the efficacy of omega-3 ethyl-eicosapentaenoic acid (E-EPA) as adjuvant to antidepressant medication in the treatment of depression in adults with diabetes mellitus. METHODS: In the VU University Medical Center, we conducted a 12-week, placebo-controlled, double-blind, parallel-group intervention study of E-EPA (1g/day) versus placebo in 25 diabetes patients meeting DSM-IV criteria for major depressive disorder, who were already using antidepressant medication. The primary outcome was severity of depressive symptoms, assessed by the Montgomery Asberg Depression Rating Scale (MADRS) at baseline and 12-week follow-up at two-weekly intervals. Blood samples were collected at baseline and at 12-week follow-up to determine EPA levels in erythrocyte membranes. Data were analyzed with ANOVA for repeated measures. RESULTS: Thirteen participants were randomly assigned to E-EPA; 12 participants were given placebo. At 12-week follow-up, erythrocyte membranes from patients receiving E-EPA contained tripled levels of EPA, while no changes were noted in participants receiving placebo. In both groups, depressive symptoms significantly decreased over time (F=21.14, p<0.001), yet no significant differences were found between those treated with E-EPA versus placebo (F=1.63, p=0.17). LIMITATIONS: Although having sufficient study power, this study had a relatively small sample size. Small effects could not be detected, and dose-dependent effects could not be studied. CONCLUSIONS: No evidence was found for the efficacy of adding E-EPA to antidepressants in reducing depressive symptoms in diabetic patients with co-morbid depression.


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder, Major/complications , Diabetes Complications/psychology , Eicosapentaenoic Acid/therapeutic use , Adjuvants, Pharmaceutic/therapeutic use , Antidepressive Agents/administration & dosage , Depressive Disorder, Major/drug therapy , Diabetes Complications/drug therapy , Double-Blind Method , Eicosapentaenoic Acid/administration & dosage , Female , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Treatment Outcome
12.
Tijdschr Psychiatr ; 50(9): 579-91, 2008.
Article in Dutch | MEDLINE | ID: mdl-18785105

ABSTRACT

BACKGROUND: Antipsychotics are effective drugs that are prescribed frequently for a large group of patients. However, they also have many side-effects which can lead ultimately to serious somatic complications. These complications fall into various categories: metabolic, cardiovascular, neurobiological, haematological, gastro-intestinal and urogenital. AIM: To make an inventory of the side-effects and advise on ways of monitoring and preventing them. method The multidisciplinary working group on somatic complications arising from the use of antipsychotics (Werkgroep Somatische Complicaties) has collected literature on the subject and has discussed it at a number of consensus meetings. results The most frequent somatic complications are described on the basis of specific risk profiles and advice is given on how to identify these complications and on how to treat them when necessary. It is essential to monitor, systematically and regularly, somatic complications arising from the use of antipsychotics; furthermore, polypharmacy should be avoided. The person ultimately responsible for this is the doctor who has prescribed the antipsychotics. In addition, it is important to draw patients' attention to the general rules for a healthy lifestyle: no smoking, a balanced diet and adequate exercise. CONCLUSION: It is very important that somatic complications should be monitored carefully and accurately. So far, the Netherlands has no official guidelines on ways to identify and treat somatic complications.


Subject(s)
Antipsychotic Agents/adverse effects , Cardiovascular Diseases/chemically induced , Gastrointestinal Diseases/chemically induced , Metabolic Diseases/chemically induced , Obesity/chemically induced , Antipsychotic Agents/therapeutic use , Cardiovascular Diseases/epidemiology , Gastrointestinal Diseases/epidemiology , Humans , Metabolic Diseases/epidemiology , Obesity/complications , Obesity/epidemiology , Risk Factors
14.
Article in English | MEDLINE | ID: mdl-15041026

ABSTRACT

Major depressive disorders (MDD) and cardiovascular disease are mutually associated. They share signs and symptoms of the "metabolic syndrome". Two observations that may be causally related with the metabolic syndrome and therefore with both MDD and cardiovascular disease are a decrease in omega-3 polyunsaturated fatty acids (PUFAs) and a rise in plasma homocysteine (tHcy) levels. Both the rise in tHcy and the decrease in omega-3 PUFAs may be associated with enhanced lipid peroxidation. We exploratively studied 44 randomly chosen patients out of a cohort of 134 patients with the recurrent form of MDD (MDD-R). We measured tHcy levels together with saturated FAs, monounsaturated fatty acids (MUFAs) and PUFAs of the omega-3, omega-6 and omega-9 series in plasma and erythrocytes. Levels were compared with laboratory reference values. The main findings were a decrease in the erythrocytes of C22:5omega-3, C22:6omega-3, C24:1omega-9 and C20:3omega-9 and in the plasma a decrease in C24:1omega-9 and C20:3omega-9. The only significant association we found was between the total of omega-6 fatty acids and plasma tHcy. The FA alterations were found in patients although most of them were clinically recovered, suggesting that the alterations may represent a biological" trait" marker for recurrent depression.


Subject(s)
Depression/blood , Fatty Acids/blood , Homocysteine/blood , Adult , Case-Control Studies , Fatty Acids, Unsaturated/blood , Female , Humans , Male , Middle Aged , Pilot Projects , Recurrence
15.
Clin Endocrinol (Oxf) ; 59(4): 459-66, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14510908

ABSTRACT

OBJECTIVE: In X-linked adrenoleucodystrophy (X-ALD) the peroxisomal beta-oxidation of saturated very long-chain fatty acids (VLCFAs; carbon length > 22 atoms) is impaired. These fatty acids accumulate in blood and tissues, in particular in the nervous system, adrenal cortex and testis. Most patients have a primary adrenocortical insufficiency with low levels of cortisol and dehydroepiandrosterone (DHEA) and its sulphate ester (DHEA-S), collectively called DHEA(S). Surprisingly, very low plasma levels of DHEA(S) may be found when plasma cortisol and ACTH levels are normal. In animal studies DHEA administration had a peroxisome proliferating effect and induced the expression of peroxisomal enzymes involved in the beta-oxidation of fatty acids. PATIENTS AND DESIGN: To study the effect of DHEA on fatty acids in X-ALD patients, we conducted a randomized double-blind study in which 14 men (age range 21-63 years) and one boy (12 years) received 50 mg of DHEA or placebo for 3 months, followed by a 1-month wash-out period, then 3 months of placebo or vice versa. RESULTS: A significant rise was seen in the plasma levels of DHEA-S, Delta4-androstenedione and IGF-I. The elevated saturated VLCFAs in plasma and erythrocytes did not change. However, in erythrocytes significant decreases were found in the total amount of fatty acids, in C16:0, C18:0 and in C20:4omega-6, C22:5omega-6, C18:1omega-9, C20:1omega-9 and C20:3omega-9. In plasma, decreases were found for C18:1omega-9 and increases for C20:1omega-9. CONCLUSIONS: Dehydroepiandrosterone supplementation for 3 months did not lower the elevated plasma levels of saturated very long-chain fatty acids in patients with X-linked adrenoleucodystrophy. Instead, a decrease in saturated and mono- and polyunsaturated fatty acids in erythrocytes and plasma was found. An increase of C20:1omega-9 was found in plasma only.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Adrenoleukodystrophy/drug therapy , Dehydroepiandrosterone/administration & dosage , Fatty Acids/blood , Adjuvants, Immunologic/blood , Administration, Oral , Adrenoleukodystrophy/blood , Adult , Androstenedione/blood , Child , Dehydroepiandrosterone/blood , Double-Blind Method , Erythrocytes/metabolism , Fatty Acids, Unsaturated/blood , Humans , Insulin-Like Growth Factor I/analysis , Male , Middle Aged
16.
Ned Tijdschr Geneeskd ; 145(40): 1943-5, 2001 Oct 06.
Article in Dutch | MEDLINE | ID: mdl-11675976

ABSTRACT

A 23-year-old woman with no psychiatric history developed acute mania and psychosis while using St. John's wort at a high dosage (Valdispert 'balans', a combination of valerian extract and hypericin). She was diagnosed as having substance-induced mood disorder, with manic features (DSM-IV). Discontinuation of the use of the product and treatment with olanzapine led to complete recovery. No causal relationship between the use of the extract and the mania was established, but the course of the mania does suggest this association. St. John's wort is a popular herbal antidepressant. Hyperforin and hypericin, components of St. John's wort, inhibit synaptosomal serotonin, noradrenaline and dopamine uptake. The mechanism of action of St. John's wort is, however, not yet fully understood. St. John's wort should therefore be used with caution, especially in patients with a bipolar disorder.


Subject(s)
Bipolar Disorder/chemically induced , Hypericum/adverse effects , Phytotherapy , Plant Extracts/adverse effects , Adult , Drug Combinations , Female , Humans , Remission Induction , Valerian/adverse effects
17.
Biol Psychiatry ; 49(6): 510-22, 2001 Mar 15.
Article in English | MEDLINE | ID: mdl-11257236

ABSTRACT

BACKGROUND: Fatty acid research in schizophrenia has demonstrated an altered cell membrane phospholipid metabolism. Erythrocyte membrane phospholipid composition closest reflects that of neuronal membranes. METHODS: (Poly)(un)saturated fatty acid concentrations were measured in the erythrocyte membranes of 19, consecutively admitted, medicated young schizophrenic patients and then compared with matched control subjects. Psychiatric symptomatology was rated with the Positive and Negative Symptom Scale and Montgomery-Asberg Depression Rating Scale. Because diet, hormones, and cannabis influence fatty acid metabolism, we included these factors in our study. RESULTS: The most distinctive findings concerned the omega-3 series: C22:5 omega-3, C22:6 omega-3 (docosahexaenoic acid), and the sum of omega-3 fatty acids were significantly decreased. Interestingly, C20:4 omega-6 (arachidonic acid) was not lowered. In the omega-9 series, higher levels of C22:1 omega-9 and lower levels its elongation product, C24:1 omega-9 (nervonic acid), were found. Interestingly, the other arm of the desaturation-elongation sequence of C18:1 omega-9, C20:3 omega-9, was lower in patients. The total omega-9 fatty acid levels were also lower in patients. CONCLUSIONS: Significant differences in erythrocyte fatty acid composition were found. The differences were not due to diet or hormonal status and could not be explained by the medication or cannabis use. No consistent pattern emerged from the different fatty acid abnormalities and the clinical symptom scores.


Subject(s)
Docosahexaenoic Acids/blood , Erythrocyte Membrane/metabolism , Fatty Acids, Unsaturated/blood , Schizophrenia/metabolism , Adolescent , Adult , Chromatography, Gas , Energy Intake , Female , Follow-Up Studies , Hormones/blood , Humans , Male , Nutritional Status , Schizophrenia/diagnosis , Schizophrenic Psychology , Surveys and Questionnaires
18.
J Neurol Neurosurg Psychiatry ; 67(3): 290-9, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10449548

ABSTRACT

OBJECTIVES: X-linked adrenoleukodystrophy (X-ALD) is an inherited disorder of peroxisomal fatty acid oxidation, biochemically characterised by the accumulation of saturated very long chain fatty acids (VLCFAs), particularly hexacosanoic acid (C26:0). Dietary treatment with a 4:1 mixture of glyceroltrioleate and glyceroltrierucate ("Lorenzo's oil") normalises plasma VLCFA concentrations, but neither ameliorates nor arrests the rapid progression of neurological symptoms in the cerebral variants of X-ALD. The efficacy of "Lorenzo's oil" in the milder phenotypes of X-ALD was assessed, as this has been much less investigated. METHODS: Twenty two patients who were treated with "Lorenzo's oil" for at least 12 months for a median period of 2.5 (range 1.0-6.0) years were studied. Two had asymptomatic ALD, four the "Addison only" variant, 13 adrenomyeloneuropathy (AMN), and three were symptomatic female carriers. RESULTS: The plasma C26:0 concentration normalised or near normalised in 19 patients (86%), in the three others it decreased significantly. Nevertheless, disability as measured with the extended disability status scale score increased mildly (0.5 (95% confidence interval (95% CI) 0.25-1.0)) in the 16 patients with neurological symptoms. Furthermore, one "Addison only" patient and one patient with AMN developed cerebral demyelination, and another "Addison only" patient developed AMN. Adrenocortical insufficiency evolved in one patient with AMN, and hypogonadism in one patient with asymptomatic ALD and two patients with AMN. Nerve conduction, evoked potential studies (SEP, BAEP, VEP), and abnormalities on cerebral MRI did not improve. On the other hand, side effects were often noted-namely, mild increases in liver enzymes (55%), thrombocytopenia (55%), gastrointestinal complaints (14%), and gingivitis (14%). We also found a mild decrease in haemoglobin concentration and leucocyte count. CONCLUSIONS: The data suggest that treatment with "Lorenzo's oil" neither improved neurological or endocrine function nor arrested progression of the disease. Furthermore, the oil often induced adverse effects. Therefore, it is advocated that "Lorenzo's oil" should not be prescribed routinely to patients with X-ALD who already have neurological deficits.


Subject(s)
Adrenoleukodystrophy/physiopathology , Dietary Fats, Unsaturated/therapeutic use , Erucic Acids/therapeutic use , Evoked Potentials/physiology , Genetic Linkage , Triolein/therapeutic use , X Chromosome , Adolescent , Adult , Brain/pathology , Brain/physiopathology , Child , Child, Preschool , Drug Combinations , Endocrine System/physiopathology , Female , Humans , Magnetic Resonance Imaging , Male
19.
Eur J Obstet Gynecol Reprod Biol ; 77(2): 205-9, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9578280

ABSTRACT

OBJECTIVE: To compare self-reports of immune-related diseases in diethylstilbestrol (DES) daughters and controls. Prenatal exposure to DES has been associated with several malformations in the lower genital tract, a higher prevalence of adenosis, and increased risk of clear cell adenocarcinoma, and estrogen-dependent tumors. Lately, reports have been published indicating a link between DES exposure and alterations in the immune system. The present study focuses on the possible clinical consequences of an affected immune system. STUDY DESIGN: DES daughters (n=170) and control women (n=123) completed questionnaires containing lists of immune-related diseases, specified into three categories (i) allergies, (ii) auto-immune disorders, and (iii) infectious diseases. RESULTS: DES daughters reported significantly more disease conditions than the controls. Analyses for separate disease categories (allergies, auto-immune disorders, infectious disease), yielded a statistically significant difference only for infectious disease. Within this last category, two infectious diseases yielded highly significant differences: bladder infection and measles. CONCLUSION: The present findings suggest that DES daughters are at higher risk of developing immune-related disease states.


Subject(s)
Diethylstilbestrol/adverse effects , Immune System Diseases/chemically induced , Prenatal Exposure Delayed Effects , Adult , Autoimmune Diseases/epidemiology , Autoimmune Diseases/immunology , Female , Humans , Hypersensitivity/epidemiology , Hypersensitivity/immunology , Immune System Diseases/epidemiology , Infections/epidemiology , Infections/immunology , Measles/epidemiology , Measles/immunology , Pregnancy , Risk Factors , Urinary Bladder Diseases/epidemiology , Urinary Bladder Diseases/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...